In patients with HFpEF, the PARAMOUNT-HF Phase II trial has demonstrated a significant reduction in NT-proBNP levels after 12 weeks of therapy with sacubitril-valsartan in comparison with valsartan (baseline: 783 pg/mL [95% CI 670–914], 12 weeks: 605 pg/mL [95% CI 512–714] vs. baseline: 862 pg/mL [95% CI 733–1012], 12 weeks: 835 pg/mL [95% CI 710–981], respectively, p = 0.005) [66]. Here, NPPB is linked to hydrops fetalis.